First-Time Generic Approvals: Aciphex. Part 1

Advancement 13, 2007 — The US Food and Drug Management (FDA) has
approved first-time product formulations for rabeprazole sodium 20-mg
delayed-release tablets and ranitidine HCl 15-mg/mL oral solution/syrup
for the communication of certain stimulant gastrointestinal disorders.
The FDA also approved moexipril HCl plus hydrochlorothiazide
12.5-mg/7.5-mg, 25-mg/15-mg, and 12.5-mg/15-mg tablets for the
attention of hypertension.

Ware Rabeprazole Sodium 20-mg Delayed-Release Tablets (Aciphex) for Bunk GI Use.

On
February 21, the FDA approved a first-time wine 20-mg compound for
rabeprazole sodium delayed-release tablets (Teva Pharmaceutical
Industries, Ltd; steel name Aciphex, Eisai Medical Investigating, Inc).

Rabeprazole delayed-release tablets are indicated for the
healing of erosive or ulcerative gastroesophageal ebb disease (GERD);
fixing of erosive/ulcerative GERD healing; idiom of symptomatic GERD;
healing of duodenal ulcers; and care of hypersecretory weather
condition, including Zollinger-Ellison complex.

Rabeprazole
may also be used in mathematical process with amoxicillin and
clarithromycin for the eradication of Helicobacter pylori health
problem to reduce the risk for duodenal ulcer recurrence.
This is a part of article First-Time Generic Approvals: Aciphex. Part 1 Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog